Monte Rosa Therapeutics Inc (GLUE) is now in the Overvalued zone, suggesting that its current forward PS ratio of 29.49 is considered Overvalued compared with the five-year average of -4.79. The fair price of Monte Rosa Therapeutics Inc (GLUE) is between 5.23 to 14.51 according to relative valuation method. Compared to the current price of 18.50 USD , Monte Rosa Therapeutics Inc By Overvalued By 27.48%.

Relative Value

Fair Zone

5.23-14.51

Current Price：18.50

27.48%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Monte Rosa Therapeutics Inc (GLUE) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Monte Rosa Therapeutics Inc (GLUE) has a current Price-to-Book (P/B) ratio of 3.85. Compared to its 3-year average P/B ratio of 1.66, the current P/B ratio is approximately 131.91% higher. Relative to its 5-year average P/B ratio of 1.78, the current P/B ratio is about 116.77% higher. Monte Rosa Therapeutics Inc (GLUE) has a Forward Free Cash Flow (FCF) yield of approximately 14.55%. Compared to its 3-year average FCF yield of -18.39%, the current FCF yield is approximately -179.12% lower. Relative to its 5-year average FCF yield of -17.36%, the current FCF yield is about -183.81% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for GLUE competitors is 21.84, providing a benchmark for relative valuation. Monte Rosa Therapeutics Inc Corp (GLUE.O) exhibits a P/S ratio of 29.49, which is 35% above the industry average. Given its robust revenue growth of 38.54%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of GLUE increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of GLUE in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is GLUE currently overvalued or undervalued?

Monte Rosa Therapeutics Inc (GLUE) is now in the Overvalued zone, suggesting that its current forward PS ratio of 29.49 is considered Overvalued compared with the five-year average of -4.79. The fair price of Monte Rosa Therapeutics Inc (GLUE) is between 5.23 to 14.51 according to relative valuation method. Compared to the current price of 18.50 USD, Monte Rosa Therapeutics Inc is Overvalued By 27.48%.

What is Monte Rosa Therapeutics Inc (GLUE) fair value?

GLUE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Monte Rosa Therapeutics Inc (GLUE) is between 5.23 to 14.51 according to relative valuation method.

How does GLUE's valuation metrics compare to the industry average?

The average P/S ratio for GLUE's competitors is 21.84, providing a benchmark for relative valuation. Monte Rosa Therapeutics Inc Corp (GLUE) exhibits a P/S ratio of 29.49, which is 35.00% above the industry average. Given its robust revenue growth of 38.54%, this premium appears sustainable.

What is the current P/B ratio for Monte Rosa Therapeutics Inc (GLUE) as of Mar 03 2026?

As of Mar 03 2026, Monte Rosa Therapeutics Inc (GLUE) has a P/B ratio of 3.85. This indicates that the market values GLUE at 3.85 times its book value.

What is the current FCF Yield for Monte Rosa Therapeutics Inc (GLUE) as of Mar 03 2026?

As of Mar 03 2026, Monte Rosa Therapeutics Inc (GLUE) has a FCF Yield of 14.55%. This means that for every dollar of Monte Rosa Therapeutics Inc's market capitalization, the company generates 14.55 cents in free cash flow.

What is the current Forward P/E ratio for Monte Rosa Therapeutics Inc (GLUE) as of Mar 03 2026?

As of Mar 03 2026, Monte Rosa Therapeutics Inc (GLUE) has a Forward P/E ratio of -8.89. This means the market is willing to pay $-8.89 for every dollar of Monte Rosa Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Monte Rosa Therapeutics Inc (GLUE) as of Mar 03 2026?

As of Mar 03 2026, Monte Rosa Therapeutics Inc (GLUE) has a Forward P/S ratio of 29.49. This means the market is valuing GLUE at $29.49 for every dollar of expected revenue over the next 12 months.

GLUE Valuation